Can Eliquis cause hair loss? It is a question raised by many patients prescribed apixaban, a widely used direct oral anticoagulant (DOAC) in the UK for conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism. Whilst some individuals report noticing hair thinning after starting Eliquis, alopecia is not listed as a recognised side effect in the UK Summary of Product Characteristics. This article examines the clinical evidence, explores other potential causes of hair loss in patients on anticoagulants, and explains when to seek medical advice.

Does Eliquis Cause Hair Loss?

Alopecia is not listed as a recognised adverse reaction in the UK Summary of Product Characteristics for Eliquis (apixaban), and no established causal link between apixaban and hair loss has been confirmed by regulators.

Experiencing these side effects? Our pharmacists can help you navigate them →

Eliquis is the brand name for apixaban, a direct oral anticoagulant (DOAC) widely prescribed in the UK to prevent blood clots in conditions such as atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism. It works by selectively inhibiting Factor Xa, a key enzyme in the coagulation cascade, thereby reducing the blood's ability to clot.

Alopecia (hair loss) is not listed as an adverse reaction in the UK Summary of Product Characteristics (SmPC) for Eliquis, as published on the electronic Medicines Compendium (emc) and reviewed by the Medicines and Healthcare products Regulatory Agency (MHRA). The drug's primary adverse effect profile centres on bleeding-related events, including bruising, nosebleeds, and gastrointestinal bleeding. The NHS apixaban patient information pages similarly do not identify hair loss among recognised side effects.

Some patients do report noticing hair thinning or shedding after starting Eliquis, and these concerns are understandable and worth taking seriously. It is important to note that there is no established, officially confirmed causal link between apixaban and hair loss based on current clinical data. That said, individual responses to medicines can vary, and the absence of a confirmed link does not mean a patient's experience is invalid. Any new or concerning symptom following a change in medication should always be discussed with a healthcare professional.

What the Clinical Evidence Says About Apixaban and Hair

Major clinical trials for apixaban, including ARISTOTLE and AMPLIFY, did not identify alopecia as a significant adverse event; evidence of a link remains limited and largely anecdotal.

A review of the pivotal clinical trials for apixaban — including the ARISTOTLE trial (Granger et al., NEJM 2011; atrial fibrillation) and the AMPLIFY trial (Agnelli et al., NEJM 2013; venous thromboembolism) — does not identify alopecia as a statistically significant adverse event associated with the drug. These large-scale, randomised controlled trials involved tens of thousands of participants and provided the foundational safety data used by regulators, including the EMA's European Public Assessment Report (EPAR) for Eliquis.

Post-marketing surveillance data, which captures real-world reports submitted after a medicine is licensed, occasionally includes isolated case reports of hair loss associated with anticoagulants as a class. Some reports in the medical literature have noted alopecia in patients taking warfarin and, less commonly, newer agents such as rivaroxaban. For apixaban specifically, the evidence remains limited and largely anecdotal, with no robust pharmacological mechanism identified to explain a direct effect on hair follicle cycling, and no established causal link has been confirmed.

Not sure if this is normal? Chat with one of our pharmacists →

It is also worth considering that telogen effluvium — a form of temporary, diffuse hair shedding triggered by physiological stress — may occur in patients who have recently experienced a serious medical event such as a pulmonary embolism or major surgery. In such cases, the hair loss is more likely attributable to the underlying illness or the stress of hospitalisation rather than the anticoagulant itself. Distinguishing between medication-related and illness-related hair loss requires careful clinical assessment.

Other Medications and Conditions That May Cause Hair Loss

Many conditions and medicines commonly prescribed alongside anticoagulants — including iron deficiency anaemia, thyroid disorders, heparin, and beta-blockers — are well-established causes of hair loss that should be excluded first.

Before attributing hair loss to Eliquis, it is important to consider the wide range of other medicines and medical conditions that are well-established causes of alopecia. Many patients taking anticoagulants are also prescribed additional medicines, and polypharmacy can complicate the identification of a single causative agent.

Medicines associated with hair loss include:

• Anticoagulants such as warfarin and heparin — heparin-induced alopecia is well documented and considered a class effect

• Beta-blockers (e.g., atenolol, propranolol)

• ACE inhibitors and certain antihypertensives — hair loss is uncommon with these agents

• Statins — alopecia is a rare reported effect

• Antidepressants, particularly SSRIs — hair loss is uncommon and usually reversible

• Thyroid medications, if doses are not optimally managed

Medical conditions that frequently cause hair thinning include:

• Hypothyroidism or hyperthyroidism

• Iron deficiency anaemia — particularly relevant in patients with chronic or recurrent bleeding

• Autoimmune conditions such as alopecia areata or lupus

• Significant psychological or physical stress

• Nutritional deficiencies, such as iron or zinc deficiency; note that biotin deficiency is rare in the UK and vitamin D deficiency as a cause of hair loss has limited evidence

In UK primary care, initial investigations for unexplained hair loss typically include a full blood count (FBC), serum ferritin, and thyroid-stimulating hormone (TSH). Further tests — such as vitamin B12, vitamin D, or zinc levels — are generally only requested if there is a specific clinical indication, rather than as a routine screen.

Given that patients on anticoagulants may have underlying cardiovascular or haematological conditions, it is entirely possible that hair loss reflects the disease burden rather than the treatment.

Important note on supplements and herbal products: Patients should not start OTC or herbal supplements for hair loss without first speaking to their GP or pharmacist. St John's Wort is a known inducer of CYP3A4 and P-glycoprotein and can significantly reduce apixaban levels, increasing the risk of blood clots — it must be avoided. Some other supplements (e.g., high-dose fish oil, ginkgo biloba, garlic, ginseng) may increase bleeding risk when taken alongside anticoagulants. Additionally, high-dose biotin supplements can interfere with certain laboratory tests, potentially affecting the interpretation of blood results. Always seek pharmacist or GP advice before starting any new supplement.

When to Speak to Your GP or Anticoagulation Clinic

Raise hair loss concerns with your GP or anticoagulation clinic, but never stop apixaban without medical advice, as this substantially increases the risk of a serious blood clot.

If you have noticed hair loss since starting Eliquis, it is advisable to raise this with your GP or anticoagulation clinic at your next appointment, particularly if the shedding is significant, progressive, or causing distress. You should not stop taking apixaban without medical advice, as doing so could substantially increase your risk of a potentially life-threatening blood clot.

You should seek prompt medical advice if you experience:

• Sudden or severe hair loss across the scalp or body

• Patchy hair loss, which may suggest alopecia areata or another specific condition requiring assessment

• Scalp inflammation, redness, pain, scaling, or scarring — these features may indicate a scarring alopecia or inflammatory scalp condition requiring earlier specialist review

• Hair loss accompanied by fatigue, weight changes, or skin changes (which may suggest a thyroid or autoimmune condition)

• Signs of anaemia, such as breathlessness, pallor, or persistent tiredness

Seek urgent medical help — contact NHS 111 or, in an emergency, call 999 — if you experience:

• Heavy or uncontrolled bleeding

• Vomiting blood or material that looks like coffee grounds

• Black, tarry, or blood-stained stools

• Coughing up blood

• Severe or sudden headache, dizziness, or weakness

Your GP can arrange relevant investigations to rule out treatable causes of hair loss and, if necessary, liaise with a haematologist or dermatologist. If your anticoagulation team suspects the medication may be contributing, they may consider whether an alternative anticoagulant is appropriate — though this decision must always be made on an individual clinical basis, weighing the risks and benefits carefully.

Patients should feel empowered to discuss any new symptoms with their healthcare team. Open communication ensures that both the anticoagulation therapy and overall wellbeing are appropriately managed.

Managing Hair Loss While on Anticoagulant Treatment

The priority is identifying and treating any underlying cause, such as iron deficiency; telogen effluvium is typically temporary and self-limiting, with regrowth usually occurring within three to six months.

For patients experiencing hair loss whilst taking Eliquis, a practical and measured approach can help manage the condition whilst maintaining safe anticoagulation. The first priority is always to identify and address any underlying, treatable cause — such as correcting an iron deficiency or optimising thyroid hormone levels — as this alone may resolve the hair shedding.

Supportive lifestyle measures that may help maintain hair health include:

• Eating a balanced diet rich in protein and iron; nutritional deficiencies (particularly iron) should be corrected under medical supervision

• Avoiding harsh chemical treatments, excessive heat styling, and tight hairstyles that place mechanical stress on hair follicles

• Using gentle, sulphate-free shampoos and conditioners

• Managing stress through regular physical activity, adequate sleep, and psychological support where needed

These measures are supportive steps rather than proven treatments for hair loss, and their benefit will depend on the underlying cause.

If telogen effluvium is identified as the cause — often triggered by a recent illness or surgery — patients can be reassured that this type of hair loss is typically temporary and self-limiting, with regrowth usually occurring within three to six months once the triggering factor resolves, as described in British Association of Dermatologists (BAD) patient information.

For persistent or patterned hair loss, referral to a dermatologist may be appropriate. Topical minoxidil is available over the counter in the UK and is used for androgenetic (pattern) hair loss; NICE clinical knowledge summaries provide guidance on its use. However, it is advisable to discuss suitability with a GP before starting, as minoxidil is not appropriate for everyone — it should be avoided during pregnancy and breastfeeding, and is not suitable for use on an inflamed, infected, or broken scalp. The appropriate strength and formulation will depend on individual circumstances.

Before starting any OTC or herbal hair product or supplement, always check with your GP or pharmacist. Some products — particularly those containing St John's Wort — can interact with apixaban and reduce its effectiveness, and certain supplements may increase bleeding risk. Do not alter your anticoagulant dose or schedule in an attempt to manage hair loss without explicit medical guidance.

Reporting Side Effects Through the MHRA Yellow Card Scheme

Patients and clinicians can report suspected side effects from Eliquis, including hair loss, via the MHRA Yellow Card scheme online, by app, or through a GP or pharmacist.

In the UK, patients and healthcare professionals are encouraged to report any suspected side effects from medicines — including Eliquis — through the MHRA Yellow Card scheme. This voluntary pharmacovigilance system plays a vital role in monitoring the ongoing safety of licensed medicines and can help identify previously unrecognised adverse effects that may not have emerged during clinical trials.

Reporting a suspected side effect does not confirm that the medicine caused it — it simply adds to the body of real-world safety data that regulators use to make informed decisions. If you believe your hair loss may be related to apixaban, submitting a Yellow Card report is a straightforward and valuable contribution to patient safety. Reports can be submitted:

• Online at yellowcard.mhra.gov.uk

• Via the Yellow Card app, available on iOS and Android

• Through your GP, pharmacist, or nurse, who can submit on your behalf

Healthcare professionals are also encouraged to report suspected adverse drug reactions, particularly for newer medicines where post-marketing data continues to accumulate. The MHRA reviews all Yellow Card reports and may update a medicine's safety information if a pattern of concern is identified.

If you are unsure whether your symptoms are worth reporting, the general guidance is: when in doubt, report. Every submission helps build a clearer picture of how medicines perform in real-world populations, ultimately improving safety for all patients.

Frequently Asked Questions